TY - JOUR
AU1 - Lu, RenJie
AU2 - Zhang, Yan
AU3 - Zhu, Xishan
AU4 - Fan, Zhengda
AU5 - Zhu, Shanmei
AU6 - Cui, Manman
AU7 - Zhang, Yanping
AU8 - Tang, Fenglei
AB - Int Urol Nephrol (2016) 48:1499–1509 DOI 10.1007/s11255-016-1319-7 NEPHROLOGY - ORIGINAL PAPER Effects of mineralocorticoid receptor antagonists on left ventricular mass in chronic kidney disease patients: a systematic review and meta‑analysis 1 2 3 1 1 RenJie Lu · Yan Zhang · Xishan Zhu · Zhengda Fan · Shanmei Zhu · 4 4 1 Manman Cui · Yanping Zhang · Fenglei Tang Received: 17 February 2016 / Accepted: 9 May 2016 / Published online: 18 May 2016 © Springer Science+Business Media Dordrecht 2016 Abstract resulted in a significant change of 0.93 SMD (standard Background Mineralocorticoid receptor antagonists mean difference) in LVM (LVMI), a significant reduction (MRAs) are used widely in treatment of heart failure, but of 22 % in all-cause mortality, a significant reduction of their effects on cardiovascular complications and mortal- incidence of MACEs (RR 0.65, P = 0.001), significantly ity of chronic kidney disease (CKD) are not well known. higher prevalence rates of hyperkalemia (>5.5 mmol/L), Thus, we aim to assess such therapeutic effects of MRAs but no significant change in prevalence rates of severe on CKD. hyperkalemia (>6.0 mmol/L). Methods Electronic literature published in any language Conclusion MRA benefits CKD patients in terms of until Dec 31, 
TI - Effects of mineralocorticoid receptor antagonists on left ventricular mass in chronic kidney disease patients: a systematic review and meta-analysis
JF - International Urology and Nephrology
DO - 10.1007/s11255-016-1319-7
DA - 2016-05-18
UR - https://www.deepdyve.com/lp/springer-journals/effects-of-mineralocorticoid-receptor-antagonists-on-left-ventricular-BHXX70i2cA
SP - 1499
EP - 1509
VL - 48
IS - 9
DP - DeepDyve
ER -